Sanofi using Berkeley Lights’ tech to catalyze cell line development

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Dr_Microbe)
(Image: Getty/Dr_Microbe)
Berkeley Lights has signed a new agreement with Sanofi through which the company will use its Beacon OptoFluidic Platform to fast-track cell line development.

Berkeley Lights, Inc. (BLI)​ is a digital cell biology company developing and commercializing platforms for the discovery, development, and delivery of cell-based products and therapies.

BLI today announced that Sanofi has purchased its Beacon OptoFluidic Platform to accelerate its cell line development (CLD) process.

According to the company, pilot study data revealed that the Beacon platform “quickly and efficiently”​ identified target secreting clones.

“The benefit of using the Beacon platform is the speed in which it can identify the top producing, stable clones to be taken into scale up,”​ Keith Breinlinger, CTO of Berkeley Lights told us. “In just 5 days, the Beacon platform can identify the top 48 clones."

Shiv Krishnan, head, technology platforms, global business development and licensing at Sanofi said: “Increasingly, automation, digitization and, miniaturization are becoming important business drivers in the discovery of medicines."

"The Beacon automated technology will help us to conduct cell line development faster, and hopefully, reduce drug development timelines,​" Krishnan told us.

"We are always hunting for technologies and tools to will help us bring important medicines to patients faster,"​ he added.

According to BLI, the Beacon platform – which is intended for research purposed only – is apt for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows.

"Customers are purchasing for a variety of use cases,"​ Breinlinger explained.

The company has several other agreements with companies, including Pfizer​, Bayer​, and Teva​, among others.

 

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars